ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Seeking Alpha
ALXO pivots to targeting HER2-positive cancer patients with high CD47 expression, supported by prior studies showing higher ORR in this subgroup. Phase 2 ASPEN-09-Breast trial expands enrollment to 120 patients, with topline data expected mid-2027; biomarker-driven strategy may enhance response prediction. A recent $140.4M capital raise extends the cash runway into H1 2028, supporting ongoing trials and strategic repositioning. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thicha Satapitanon/iStock via Getty Images The last time I spoke about ALX Oncology ALXO it was with respect to a Seeking Alpha article entitled " ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ". The More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [Seeking Alpha]Seeking Alpha
- ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
ALXO
Earnings
- 2/27/26 - Miss
ALXO
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 3
- 2/27/26 - Form 8-K
- ALXO's page on the SEC website